+91 8617752708

British Journal of Medicine and Medical Research, ISSN: 2231-0614,Vol.: 14, Issue.: 3


ASpirin and Plavix Following Coronary Artery Bypass Grafting (ASAP-CABG): A Randomized, Double-Blind, Placebo-Controlled Pilot Trial


Ahmad M. Slim1*, Emilio Fentanes1, Dustin M. Thomas1, Jennifer N. Slim2, Taylor Triana1, Homayoun R. Ahmadian1, Ryan J. McDonough1, Jason Saucedo1, Norma J. Suarez1, Dorette Pearce-Moore1, H. Lester Kirchner3, Edward Hulten4, Ricardo C. Cury5 and Kelley Branch6

1Cardiology Service, San Antonio Military Medical Center, 3551 Roger Brooke Drive, San Antonio, Texas 78234-6200, USA.

2Louisiana State University, New Orleans, LA, USA.

3Geisinger Medical Center, Danville, PA, USA.

4Cardiology Service, Walter Reed National Military Medical Center, Bethesda, MD, USA.

5Department of Radiology, Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, USA.

6Division of Cardiology, University of Washington, Seattle, WA, USA.

Article Information
(1) Vijayalakshmi I. Balekundri, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Bengaluru, India.
(2) Nurhan Cucer, Erciyes University, Medical Biology Department, Turkey.
(3) Philippe E. Spiess, Department of Genitourinary Oncology, Moffitt Cancer Center, USA and Department of Urology and Department of Oncologic Sciences (Joint Appointment), College of Medicine, University of South Florida, Tampa, FL, USA.
(1) Gerez Fernandes Martins, Institute of Rio de Janeiro, Brazil.
(2) Gibran Roder Feguri, General University Hospital, Brazil.
Complete Peer review History: http://sciencedomain.org/review-history/13503


Background: Vein graft thrombosis is the leading cause of acute graft failure within the first post-operative month. Several studies have shown the benefit of post-operative dual anti-platelet therapy (DAPT) in preventing acute graft thrombosis. The purpose of this study was to determine whether peri-operative initiation of DAPT will improve short and intermediate term graft patency.

Methods: This was a randomized, double-blind, placebo controlled trial of 20 patients undergoing CABG to compare DAPT versus aspirin monotherapy. The primary outcome was post-operative graft patency at 2 and 52 weeks determined by <50% bypass graft stenosis by cardiac computed tomography angiography (CCTA). The secondary outcomes were (1) major adverse cardiovascular events (MACE), defined as myocardial infarction, thrombotic events, and angina, and (2) safety end-points defined as TIMI major and minor bleeding events.

Results: The study population consisted predominately of men (19/20 patients). At 2 weeks, all LIMA grafts were patent although vein graft patency for the DAPT group was only 83.3% (20/24) compared to 89.5% (17/19) for placebo (p=0.597). At 52 weeks, the patency rate in the placebo group was 52.6% (10/19) as compared to a patency of 71.4% (15/24) in the dual anti-platelet therapy arm (p=0.244). 

Conclusion: The addition of clopidogrel to aspirin post-bypass surgery did not significantly improve venous graft patency at 2 weeks but trended toward higher graft patency at 52 weeks.

Keywords :

Aspirin; Plavix; CCTA; coronary artery bypass surgery; graft patency; major adverse cardiovascular events.

Full Article - PDF    Page 1-10

DOI : 10.9734/BJMMR/2016/24386

Review History    Comments

Our Contacts

Guest House Road, Street no - 1/6,
Hooghly, West Bengal,

+91 8617752708


Third Floor, 207 Regent Street
London, W1B 3HH,

+44 20-3031-1429